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Abstract
Biological agents, including TNF inhibitors, have revolutionized the treatment of RA in recent years.
Certolizumab pegol (CZP) is a novel pegylated anti-TNF approved for the treatment of adult patients
with moderately to severely active RA. This article provides an overview of three published clinical trials
of CZP in RA in patients with active disease who have shown an inadequate response to DMARDs,
including MTX: RA prevention of structural damage (RAPID) 1 and 2, which evaluated the efficacy and
safety of CZP added to MTX when dosed every 2 weeks, and efficacy and safety of CZP – 4 weekly
dosage in rheumatoid arthritis (FAST4WARD), which evaluated CZP monotherapy when dosed every
4 weeks. In the trials, CZP plus MTX or as monotherapy significantly improved the signs and symptoms
of RA and RA disease activity, and CZP plus MTX significantly inhibited the progression of radiographic
joint damage as early as Week 16 of the treatment. In addition, CZP treatment significantly improved
patient-reported outcome measures, providing significant reductions in pain and fatigue and improve-
ments in physical function as early as Week 1 of treatment; improvements in health-related quality of
life were evident at the first assessment at Week 12. CZP treatment improved productivity at work,
significantly reducing the number of days of missed work as well as the number of days with reduced
productivity, and also increased productivity within the home and improved participation in family, social
and leisure activities. CZP was generally well tolerated when used either as monotherapy or added to
MTX; most adverse events were mild or moderate. Taken together, the results of these trials suggest that
CZP is an effective new option for the treatment of RA.
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Introduction
The introduction of biological TNF-a inhibitors was a sig-
nificant advance in the management of RA [1]. However,
while many patients respond well to these agents, others
may never respond, and some patients may stop re-
sponding over time or may need to switch or discontinue
therapy because of tolerability issues. There is thus a
continuing need for new RA treatments.
Certolizumab pegol (CZP) is a novel pegylated
anti-TNF, consisting of a Fab0 attached to a 40-kDa
PEG moiety. Attachment of PEG to the Fab0 increases
the plasma half-life of CZP to  2 weeks, allowing dosing
every 2 or 4 weeks, and may contribute to the preferen-
tial distribution of the drug to inflamed tissues that has
been observed in animal models [2]. CZP lacks an Fc
region, so it does not induce complement- or
antibody-dependent cell-mediated cytotoxicity, which
has been observed in vitro with adalimumab, etanercept
and infliximab [3]. CZP is approved in the USA, Canada
and Europe for the treatment of adult patients with mod-
erately to severely active RA, and in the USA and
Switzerland for the treatment of patients with Crohn’s
disease.
The efficacy and safety of CZP in adult patients with
active RA were established in three Phase III clinical
trials, in which CZP was administered with MTX or as
monotherapy [4–6]. These studies demonstrated that
CZP reduces the clinical signs and symptoms of active
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WRA and inhibits the progression of structural joint damage.
The trials also assessed a number of patient-reported out-
comes (PROs), including health-related quality of life
(HRQoL), fatigue, pain, physical function and household/
work productivity. PROs assess the impact of RA on
everyday life from the patient’s perspective and are
being increasingly recognized as important measures for
inclusion in RA clinical trials. Together with physician-
reported outcomes, PROs help to provide a more com-
prehensive evaluation of the efficacy of RA therapy. This
article thus provides an overview of the efficacy and safety
data for CZP from these three pivotal trials, with a particu-
lar focus on the PRO and productivity results.
Article search
The PubMed database was searched (all years) to identify
articles reporting data from Phase III clinical trials of CZP
in RA, using the search terms ‘certolizumab pegol’ or its
trade name as marketed by UCB in the title. Additional
articles were identified from abstracts published on
major rheumatology congress web sites including the
EULAR (2006–09) and ACR (2006–09).
Clinical efficacy of CZP
CZP plus MTX
The RA prevention of structural damage (RAPID) 1 and
2 trials were Phase III, multi-centre, randomized, double-
blind placebo-controlled trials, which evaluated the effi-
cacy and safety of CZP plus MTX in adults (n=982 and
619, respectively) with active RA despite treatment with
MTX [4, 5]. RAPID 1 was a 52-week trial of a lyophilized
formulation of CZP, while RAPID 2 was a 24-week trial of a
liquid formulation. Patients aged 518 years with adult-
onset RA (56 months but <15 years) were randomized
2:2:1 to one of two regimens of s.c CZP (400mg at
Weeks 0, 2 and 4, followed by 200 or 400mg) plus MTX
every 2 weeks, or placebo plus MTX. Notably, withdrawal
for ACR20 non-response was mandatory for these trials;
patients who failed to demonstrate ACR20 improvement
at both Weeks 12 and 14 were to be withdrawn and
allowed to enter an open-label extension study of CZP
400mg plus MTX every 2 weeks. Patients who completed
the studies were also allowed to enter open-label treat-
ment. The primary efficacy endpoint for both trials was the
proportion of patients achieving a 20% improvement in
the ACR response criteria at Week 24 [7]. Mean change
from baseline in modified total Sharp score (mTSS)
at Week 52 was a co-primary endpoint in RAPID 1.
Secondary endpoints in both studies included ACR50
and ACR70 responder rates, mean change from baseline
in 28-joint DAS assessment (ESR) [DAS-28 (ESR)]
and PROs.
The majority of patients had high disease severity at
baseline (Table 1). In both trials, the onset of symptom
relief with CZP was rapid. ACR20 response rates were
significantly higher with CZP plus MTX than placebo
plus MTX at Week 1 (22.9 and 14.3% with CZP 200mg
plus MTX vs 5.6 and 3.3% with placebo plus MTX in the
RAPID 1 and 2 trials, respectively) [4, 5]. ACR20 response
rates peaked at Week 12 in both studies (63.8 and 62.7%
for CZP 200mg vs 18.3 and 12.7% for placebo in RAPID 1
and 2, respectively; both P<0.001). At Week 24, ACR20
response rates were 58.8 and 57.3% for patients receiving
CZP 200mg plus MTX, respectively, vs 13.6 and 8.7%.
TABLE 1 Baseline characteristics of patients in the RAPID 1, 2 (ITT populations) and FAST4WARD (modified ITT
population) trials [4–6]
Baseline characteristics
RAPID 1
(n=982)
RAPID 2
(n=619)
FAST4WARD
(n=220)
Age, mean (S.D.), years 52.0 (11.6) 51.9 (11.5) 53.8 (12.2)
Sex, female, % 83.2 81.6 83.6
Duration of RA, mean (S.D.), years 6.1 (4.3) 6.2 (4.2) 9.5 (8.9)
No. of previous DMARDs, mean (S.D.) 2.3 (1.3) 2.2 (1.3) 2.0 (1.2)
MTX dose, mean, mg/week 13.6 12.5 NA
RF positive, 514IU/ml, % 81.8 76.9 100
Tender joint count, mean (S.D.) 30.7 (12.9) 30.2 (14.0) 29.0 (13.1)
Swollen joint count, mean (S.D.) 21.5 (9.8) 21.0 (9.8) 20.5 (9.7)
Patient’s assessment of arthritis pain (0–100mm VAS), mean (S.D.) 63.1 (18.9) 60.9 (20.2) 56.5 (21.4)
HAQ-DI, mean (S.D.) 1.7 (0.6) 1.6 (0.6) 1.5 (0.6)
DAS-28 (ESR), mean (S.D.) 6.9 (0.8) 6.8 (0.8) 6.3 (1.0)
CRP, geometric mean (CV), mg/l 14.7 (144.2) 13.6 (180.9) 11.5 (233.1)
FAS (0–10), mean (S.D.) 6.5 (2.0) 6.5 (1.9) 6.3 (2.2)
SF-36 PCS, mean (S.D.) 30.8 (6.5) 30.9 (6.2) 27.9 (7.8)
SF-36 MCS, mean (S.D.) 39.4 (11.2) 39.3 (11.0) 44.7 (11.5)
The ITT populations for RAPID 1 and 2 consisted of all patients who were randomized into the studies; the modified ITT
population for FAST4WARD consisted of all randomized patients who had taken one or more dose of study medication.
Adapted from Mease [21] with permission of Future Medicine Ltd. CV: coefficient of variation; ITT: intention-to-treat; NA: not
applicable.
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CZP vs placebo groups were seen from Weeks 2 and 4 in
RAPID 1, and Weeks 6 and 20 in RAPID 2, respectively.
Responses were sustained to the end of the trials (Week
52 in RAPID 1 and Week 24 in RAPID 2; Table 2), and were
similar in the CZP 400mg plus MTX groups. CZP treat-
ment also yielded significant improvements in all ACR
core component scores, including reductions in swollen
and tender joint scores and improvements in both
patient’s and physician’s global assessments of disease
activity, by Week 1 that were sustained throughout both
studies [4, 5].
Treatment with CZP plus MTX was associated with sig-
nificantly greater improvements in disease activity from
Week 1, as evidenced by DAS-28 (ESR) scores, through-
out both trials (P<0.001 at all time points) [4, 5]. At
Week 1, mean change from baseline in DAS-28 was
 0.8 with CZP 200mg and  0.3 with placebo in
RAPID 1, and  0.8 with CZP 200mg and  0.2 with pla-
cebo in RAPID 2. Improvements were sustained to the
end of both studies (52 or 24 weeks, respectively;
Fig. 1), and were similar with the CZP 400mg dose. In
RAPID 2, DAS-28 remission was observed in 9.4% of
patients treated with CZP 200mg plus MTX compared
with only 0.8% of patients in the placebo group [5].
Both trials investigated the effects of CZP on the pro-
gression of joint damage. In RAPID 1, the mean (S.D.)
change in mTSS from baseline to Week 52, which was a
co-primary endpoint of the study, was significantly lower
in patients receiving CZP 200mg plus MTX [0.4 (5.7) in the
CZP 200mg group] compared with patients receiving pla-
cebo plus MTX [2.8 (7.8); P<0.001] [4]. The changes
were also significantly lower in the CZP plus MTX
groups vs the placebo plus MTX group at Week 24
(P<0.001). At both time points, significantly lower mean
changes from baseline in both erosion (Week 24: 0 vs 0.7,
Week 52: 0.1 vs 1.5; P<0.001) and joint space narrowing
subscores (Week 24: 0.2 vs 0.7, Week 52: 0.4 vs 1.4;
P40.01) were observed in patients receiving CZP
200mg plus MTX. Similarly, in RAPID 2, the mean (S.D.)
change in mTSS from baseline at Week 24 was signifi-
cantly lower in patients receiving CZP 200mg plus MTX
[0.2 (2.7)] compared with patients receiving placebo plus
MTX [1.2 (4.1)] (P40.01) [5]. Patients in the CZP 200mg
group in RAPID 2 also had significantly lower erosion
(mean change from baseline: 0.1 vs 0.7) and joint space
narrowing (mean change from baseline: 0.1 vs 0.5)
subscores (P40.01). Results for patients receiving the
400-mg dose were similar. An analysis of joint damage
in patients who withdrew from the trials at Week 16 due
to ACR20 non-response at Weeks 12 and 14 (as man-
dated by the study protocol) found that radiographic pro-
gression was inhibited by CZP plus MTX despite the fact
that these patients did not meet the threshold for a clinical
response [4, 5]. These observations suggest that the rapid
effects of CZP may lead to long-term benefits for patients
in terms of slowing disease progression.
As mentioned above, patients who either withdrew from
the RAPID 1 and 2 trials due to ACR20 non-response or
who completed the studies were allowed to enter an
open-label extension study of CZP 400mg plus MTX.
Recently reported results from this study indicate that
the improvements in RA signs and symptoms and disease
activity and the inhibition of joint damage progression
were sustained over 2 years [8].
CZP monotherapy
Efficacy and safety of CZP – 4 weekly dosage in
rheumatoid arthritis (FAST4WARD) was a Phase III,
24-week, multi-centre, randomized, double-blind placebo-
controlled trial evaluating the efficacy and safety of CZP
TABLE 2 ACR response rates (%) at study end in RAPID 1 (Week 52), RAPID 2 (Week 24) and FAST4WARD (Week 24)
[4–6]
Study ACR20 ACR50 ACR70
RAPID 1
a,b
Placebo+MTX Q2W (n=199) 13.6 7.6 3.5
CZP 200mg+MTX Q2W (n=393) 53.1, P<0.001 38.0, P<0.001 21.2, P<0.001
CZP 400mg+MTX Q2W (n=390) 54.9, P<0.001 39.9, P<0.001 23.2, P<0.001
RAPID 2
a,b
Placebo+MTX Q2W (n=127) 8.7 3.1 0.8
CZP 200mg+MTX Q2W (n=246) 57.3, P<0.001 32.5, P<0.001 15.9, P40.01
CZP 400mg+MTX Q2W (n=246) 57.6, P<0.001 33.1, P<0.001 10.6, P40.01
FAST4WARD
c,d
Placebo Q4W (n=109) 9.3 3.7 0
CZP 400mg Q4W (n=111) 45.5, P<0.001 22.7, P<0.001 5.5, P40.05
aITT population: analyses performed using non-responder imputation.
bDosing every 2 weeks (Q2W).
cModified ITT popula-
tion: analyses performed using non-responder imputation.
dDosing every 4 weeks (Q4W). P-values vs placebo plus MTX or
placebo alone. ACR20/ACR50/ACR70 responses for the CZP and placebo groups were compared using logistic regression
with treatment and geographical region as factors in the RAPID trials or a Cochran–Mantel–Haenszel test stratified by country
in the FAST4WARD trial. Details of the statistical analyses are provided in the primary publications for the trials [4–6].
ITT: intention-to-treat.
www.rheumatology.oxfordjournals.org 263
Certolizumab pegol in the treatment of RAmonotherapy in 220 adults with active RA who had
failed therapy with at least one prior DMARD [6].
Patients aged 18–75 years with adult-onset RA were ran-
domized to receive a lyophilized formulation of CZP
400mg or placebo subcutaneously every 4 weeks.
Patients completing the trial or withdrawing on or after
Week 12 were offered entry into an open-label study of
CZP 400mg every 4 weeks unless they were withdrawn
because of non-compliance or possible treatment-related
adverse events (AEs). The primary endpoint was ACR20
response at Week 24; radiographic assessments were not
performed in this trial. Secondary endpoints included
ACR50 and ACR70 responder rates, DAS-28 (ESR) and
PROs.
Patients in this trial also had high disease activity at
baseline (Table 1). ACR20 response rates were significant-
ly higher with CZP than placebo from Week 1 (36.7 vs
6.6%; P<0.001) onwards [6]. At Week 12, ACR20 re-
sponse rates were 47.7 and 8.5% for patients taking
CZP 400mg and placebo, respectively (P<0.001), and
remained significantly higher for CZP until the study end
(Table 2). ACR50 and ACR70 responses were significantly
higher with the CZP 400mg group from Weeks 1 and 8
onwards, respectively, and significantly greater improve-
ments in DAS-28 (ESR) were observed with CZP mono-
therapy from Week 1 onwards (P<0.001 at all time points)
[6]. At Week 1, least square mean changes from baseline
in DAS-28 (ESR) were  0.9 and  0.3 in the CZP and pla-
cebo groups, respectively. Improvements were sustained
to Week 24 (Fig. 1).
Effect of CZP on HRQoL, fatigue, pain
and physical function
PROs were also assessed as secondary endpoints in
all three trials and included HRQoL, fatigue, arthritis pain
and physical function. HRQoL was assessed using the
short-form 36 (SF-36)-item health survey questionnaire
(which assesses physical functioning, role physical,
bodily pain, general health, vitality, social functioning,
role emotional and mental health) [9]. Scores for the phys-
ical component summary (PCS, mainly comprising the
physical functioning, role physical, bodily pain and general
health domains) and mental component summary (MCS,
mainly comprising the vitality, social functioning, role
emotional and mental health domains) were also obtained.
Fatigue over the previous week was assessed using the
Fatigue Assessment Scale (FAS), a numerical rating scale
[10], and arthritis pain was assessed using a 0- to 100-mm
visual analogue scale (VAS) [11]. Daily pain assessments
were also performed in FAST4WARD during the first week
using a modified brief pain inventory (mBPI), which asked
patients to rate their worst pain in the past 24h, average
pain in the past 24h and pain right now. Physical function
was assessed using the HAQ-disability index (HAQ-DI)
[12, 13].
The proportion of patients achieving minimum clinically
important differences (MCIDs) in HRQoL, fatigue, pain and
physical function was also determined. MCIDs for the
SF-36 domains are defined as 55.0-point increases
from baseline, and for the PCS and MCS as 52.5-point
increases from baseline [14]. The MCIDs for the HAQ-DI,
pain and FAS are defined as a 50.22-point decrease
from baseline [15], a 510-mm reduction from baseline
[11, 15, 16] and a 1-point reduction from baseline [17],
respectively.
CZP plus MTX
From the initial assessment at Week 12, significantly more
patients treated with CZP plus MTX than placebo plus
MTX reported statistically significant and clinically mean-
ingful improvements in all SF-36 domains, PCS and MCS
that were sustained through 52 (RAPID 1) or 24 (RAPID 2)
weeks (Table 3 shows PCS and MCS scores at study end)
(P<0.001) [5, 18–20]. At Week 52 in RAPID 1, 42 and 39%
of patients treated with CZP 200mg plus MTX achieved
improvements greater than or equal to MCID in SF-36
PCS and MCS scores, respectively, compared with only
11 and 10% of patients in the placebo group (P<0.001),
while at Week 24 in RAPID 2, 44 and 40% of CZP
200mg-treated patients achieved improvements greater
than or equal to MCID in SF-36 PCS and MCS scores,
respectively, vs only 9 and 8% of placebo patients. Of
note were the significant improvements in SF-36 MCS
scores following CZP treatment, which have not previ-
ously been observed with other TNF inhibitors [19].
Results were similar in patients who received CZP
400mg plus MTX.
Statistically significant reductions in fatigue and arthritis
pain scores were reported by patients receiving CZP plus
MTX at Week 1 and were sustained to either Week 52
(RAPID 1) or Week 24 (RAPID 2) (P<0.001 for both CZP
dose groups; Table 3) [4, 5, 21, 22]. CZP-treated patients
also reported significant improvements from baseline in
physical function compared with patients receiving pla-
cebo plus MTX, as early as Week 1 (P<0.001 for both
FIG.1Mean change in DAS-28 from baseline to study
end in the RAPID 1 (Week 52), RAPID 2 (Week 24) and
FAST4WARD (Week 24) trials [4–6]. RAPID 1 and 2 com-
pared CZP plus MTX Q2W vs placebo plus MTX Q2W;
FAST4WARD compared CZP monotherapy Q4W vs pla-
cebo alone Q4W. *P40.001 vs placebo plus MTX.
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from baseline in HAQ-DI scores were  0.27 and  0.20 in
the CZP 200mg groups in RAPID 1 and 2 vs  0.11 and
 0.05 in the placebo groups, respectively (P<0.001).
These rapid benefits continued to improve and were sus-
tained throughout both trials (Table 3). Clinically meaning-
ful improvements in physical function were also reported
following CZP treatment, as defined by improvements
greater than or equal to MCID, from Week 1 in RAPID
1 (43% for patients receiving CZP 200mg plus MTX vs
25% of placebo patients; P<0.001) and Week 2 in
RAPID 2 [4, 5, 20, 22]. By study end, 47 and 57% of
patients receiving CZP 200mg plus MTX reported
improvements in HAQ-DI greater than or equal to MCID
in RAPID 1 (Week 52) and 2 (Week 24), respectively,
compared with 13 and 11% of patients receiving placebo
plus MTX (P<0.001) [5, 18].
In patients who successfully completed the RAPID 1
trial and entered the open-label extension study of CZP
400mg plus MTX every 2 weeks, improvements in HRQoL
and physical function and reductions in pain and fatigue
were maintained through 100 weeks of treatment at aver-
age levels at least three times higher than the thresholds
for meaningful improvement [23].
CZP monotherapy
Patients treated with CZP monotherapy reported statistic-
ally significant improvements in HRQoL (all eight SF-36
domains as well as PCS and MCS scores) at Week 24
vs placebo (P<0.001) [6]. Significantly more CZP-treated
patients also reported improvements in HRQoL that met
or exceeded MCID throughout the study period in all
SF-36 domains, PCS and MCS (P40.05) with the excep-
tion of the role emotional domain at Week 4 (P=0.613)
and Week 12 (P=0.091) [24]. Clinically meaningful im-
provements in PCS and MCS were achieved by 46 and
34% of patients receiving CZP at Week 24, respectively,
compared with 16 and 7% of patients receiving placebo
(P<0.001) [6].
Significant and clinically meaningful reductions in fa-
tigue were reported by patients receiving CZP mono-
therapy vs placebo at Week 1 (P40.01) and were
sustained to Week 24 (P<0.001; Table 3), when clinically
meaningful reductions in fatigue were reported by 46% of
CZP patients vs 17% of placebo patients (P<0.001) [6].
Arthritis pain, which was assessed daily (mBPI scale)
during the first week of treatment in the FAST4WARD
study, was significantly reduced in patients receiving
CZP vs placebo by Day 2 (P40.05) [6]. At Week 1, the
TABLE 3 Mean change from baseline to study end in SF-36 PCS, SF-36 MCS, FAS, pain VAS and HAQ-DI scores in
RAPID 1, 2 and FAST4WARD (ITT population) [4–6, 18, 21, 22]
RAPID 1,
a,b,c adjusted
mean change (S.E.M.)
Placebo+MTX Q2W
(n=199)
CZP 200mg+MTX Q2W
(n=393)
CZP 400mg+MTX Q2W
(n=390)
Week 52
SF-36 PCS 1.7 (0.6) 7.8 (0.4), P<0.001 8.6 (0.4), P<0.001
SF-36 MCS 2.1 (0.8) 6.4 (0.6), P<0.001 6.4 (0.6), P<0.001
Fatigue (FAS)  0.8 (0.2)  2.6 (0.1), P<0.001  2.5 (0.1), P<0.001
Arthritis pain (VAS)  8.8 (1.6)  31.0 (1.2), P<0.001  33.5 (1.2), P<0.001
Physical function (HAQ-DI)  0.18 (0.04)  0.60 (0.03), P<0.001  0.63 (0.03), P<0.001
RAPID 2,
a,b,c adjusted
mean change (S.E.M.)
Placebo+MTX Q2W
(n=127)
CZP 200mg+MTX Q2W
(n=246)
CZP 400mg+MTX Q2W
(n=246)
Week 24
SF-36 PCS 0.9 (0.7) 5.2 (0.5), P<0.001 5.5 (0.5), P<0.001
SF-36 MCS 1.6 (0.9) 6.1 (0.7), P<0.001 6.3 (0.7), P<0.001
Fatigue (FAS)  0.5 (0.2)  2.0 (0.1), P<0.001  2.2 (0.1), P<0.001
Arthritis pain (VAS)  4.7 (1.9)  23.7 (1.4), P<0.001  26.1 (1.4), P<0.001
Physical function (HAQ-DI)  0.14 (0.04)  0.50 (0.03), P<0.001  0.50 (0.03), P<0.001
FAST4WARD,
d,e,f least square
mean change Placebo Q4W (n=109) CZP 400mg Q4W (n=111)
Week 24
SF-36 PCS NA NA NA
SF-36 MCS NA NA NA
Fatigue (FAS)
e  0.3 NA  1.7, P<0.001
Arthritis pain (VAS)
b 1.7 NA  20.6, P<0.001
Physical function (HAQ-DI)
b 0.13 NA  0.36, P<0.001
aITT population.
bAnalyses performed using last observation carried forward approach.
cDosing every 2 weeks.
dModified ITT
population.
eAnalyses based on observed data.
fDosing every 4 weeks. P-values vs placebo plus MTX or placebo alone.
Analyses were performed using analysis of covariance, with treatment and geographical region as factors and baseline value
as covariate. ITT: intention-to-treat; NA: not available.
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from baseline were  16.7 vs  5.2 for the CZP and
placebo groups (P<0.001), respectively, and pain relief
continued to improve to Week 24 (P<0.001; Table 3).
At study end (Week 24), significantly more patients receiv-
ing CZP monotherapy reported clinically meaningful
reductions in arthritis pain (47 vs 17%, respectively;
P<0.001) [6].
Patients treated with CZP 400mg monotherapy re-
ported statistically significant improvements in physical
function compared with patients receiving placebo from
Week 1 ( 0.23 vs 0.04, respectively) through Week 24
( 0.36 vs 0.13; P<0.001 for both time points; Table 3)
[6]. By study end (Week 24), 49% of patients receiving
CZP reported clinically meaningful improvements in
physical function vs 12% of those receiving placebo
(P<0.001) [6].
Effects on home and work productivity
The validated RA-specific Work Productivity Survey
(WPS-RA) questionnaire was used to assess the impact
of RA on productivity in the workplace and in the home
and on participation in family, social and leisure activities
[25]. The survey assesses employment status, productiv-
ity at work for employed patients, productivity at home
and daily activities.
CZP plus MTX
Patients receiving CZP plus MTX reported less loss of
productivity at home compared with placebo patients;
this improvement began as early as Week 4 (first assess-
ment), when CZP 200mg plus MTX patients reported (on
average) significantly fewer household work days missed
per month vs placebo plus MTX patients (6.9 vs 7.6, re-
spectively), as well as significantly fewer household work
days per month with productivity reduced by at least half
(8.1 vs 9.8, respectively), fewer days per month with out-
side hired help (3.5 vs 4.1, respectively) and a lower rate of
RA interference with household work productivity (5.0 vs
5.9, respectively, on a 0–10 scale, with 0=no interference
and 10=complete interference; P40.05; RAPID 1 study)
[26]. These improvements were sustained to the end of
both RAPID 1 (52 weeks) and RAPID 2 (24 weeks), as is
evidenced in Fig. 2, which shows home productivity at
baseline and study end. Over 1 year, treatment with
CZP 200mg plus MTX resulted in an annual average of
52.1 fewer full household work days missed and
36.6 fewer days with reduced productivity due to RA com-
pared with placebo plus MTX [26].
Patients receiving CZP plus MTX also reported signifi-
cant reductions in the number of lost days of family, social
and leisure activities due to RA compared with patients
receiving placebo plus MTX by Week 4 (first assessment)
[26]. For example, patients receiving CZP 200mg plus
MTX in RAPID 1 reported an average of 4.3 days of lost
participation at Week 4 compared with 5.2 days for pla-
cebo plus MTX patients (P40.05). Improvements were
again sustained to study end (Fig. 2). Over 1 year in
RAPID 1, these reductions translated into an average
cumulative gain of 26.8 days of family, social and leisure
activities compared with placebo plus MTX [26]. Results
for all household productivity and family activity measures
were similar for the CZP 400mg plus MTX group in RAPID
1 (data not shown) and both CZP plus MTX groups in
RAPID 2 (data not shown for CZP 400mg plus MTX) [26].
In addition to improving home productivity, treatment
with CZP plus MTX rapidly improved productivity at
work [26]. At Week 4 in RAPID 1, patients receiving CZP
200mg plus MTX reported an average of 1.5 work days
missed per month and 4.3 work days per month with
productivity reduced by at least half (presenteeism), com-
pared with 2.5 and 6.5 days, respectively, in the placebo
plus MTX group (P40.05). The monthly rate of RA inter-
ference with work productivity was also significantly lower
in CZP-treated patients (3.5 vs 4.2, on a 0–10 scale, with
0=no interference and 10=complete interference).
These improvements were again sustained to study end
(Fig. 3). Over 1 year in RAPID 1, this resulted in an average
cumulative gain of 41.9 full work days and 29.4 fewer
days with reduced productivity due to RA compared
with treatment with placebo plus MTX [26]. Similar
trends were reported by patients receiving CZP 400mg
plus MTX in the RAPID 1 trial (data not shown), and by
patients in both CZP plus MTX groups in RAPID 2 (data
not shown for CZP 400mg plus MTX), although reductions
in absenteeism did not attain statistical significance in
RAPID 2.
A post hoc analysis of these trials found that these im-
provements in productivity were closely reflected by simi-
lar changes in pain, physical function and fatigue. Patients
who achieved improvements greater than or equal to
MCID in fatigue, pain and physical function reported
greater improvements in productivity at work and home
and increased participation in family, social and leisure
activities [27].
CZP monotherapy
CZP monotherapy also provided rapid and sustained im-
provements in home and work productivity as early as
Week 4 compared with placebo. At Week 4, CZP-treated
patients reported 5.2 days of household work lost com-
pared with 8.4 days in the placebo group, 5.8 days of
household work with productivity reduced by 550% vs
9.4 days for placebo, and 1.5 lost days of family, social
and leisure activities compared with 2.9 days with pla-
cebo [20]. CZP monotherapy decreased the number of
work days with reduced productivity to an average of 2.8
compared with 4.6 days for the placebo group at Week
4, and employed patients reported a lower mean rate of
interference by RA compared with placebo-treated pa-
tients (2.9 vs 4.3) [20]. At Week 24, CZP 400mg mono-
therapy was associated with cumulative gains of 25.5
additional full household work days; 27.6 additional pro-
ductive household days; 14.0 days of family, social and
leisure activities; 4.1 full paid work days; and 21.0 more
productive work days compared with patients who
received placebo [28].
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CZP plus MTX
Mandatory withdrawal of ACR20 non-responders at Week
16 and the 2:1 randomization ratio in RAPID 1 and 2 re-
sulted in longer mean exposure to study drug in the CZP
plus MTX groups than the placebo plus MTX groups [4, 5].
The pooled frequencies of treatment-emergent AEs
(TEAEs) in these two trials were therefore expressed as
the incidence rates per 100 patient-years (pt-yrs; Table 4).
Most AEs were mild to moderate, and rates of with-
drawal due to AEs were low across the groups. TEAEs
led to death in seven patients in RAPID 1 and two patients
in RAPID 2, but all were considered unlikely to be related
or unrelated to administration of the study drug. TEAEs
leading to death included myocardial infarction, hepatic
FIG.2Effect of CZP on productivity at home and on social, family and leisure activities in the RAPID 1 (Week 52) and
RAPID 2 (Week 24) trials [26]. Results are shown at baseline and study end. (A) Household work days missed due to
arthritis per month. (B) Days with household work productivity reduced by 550% due to arthritis per month. (C) Days with
outside help hired due to arthritis per month. (D) RA interference with household work productivity per month (0–10 scale,
0=no interference, 10=complete interference). (E) Days of lost family, social and leisure activities per month. The
analysis population in RAPID 1 and 2 trials was the intention-to-treat population. *P40.05 vs placebo plus MTX.
Analyses were performed using a non-parametric bootstrap t-test and the last observation carried forward approach.
Adapted from Kavanaugh et al. [26] with permission of John Wiley & Sons Inc.
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and fatigue, and femur fracture and shock. Rates of infec-
tion were comparable across the groups. Urinary tract
infections and upper respiratory tract infections (including
nasopharyngitis) were the most frequently reported infec-
tious AEs [4, 5]. Serious infections occurred more fre-
quently in the CZP plus MTX groups than in the placebo
plus MTX groups. The most frequently reported serious
infections in the CZP plus MTX groups were tuberculosis,
pneumonia and erysipelas. The 10 cases of tuberculosis
all occurred in countries with high incidence rates of the
disease (Bulgaria, Estonia, Latvia, Poland, Russia and the
Ukraine) [4, 5].
Malignant neoplasms occurred at similar rates across
the treatment groups. Malignancy affected 12 patients in
RAPID 1, including one in the placebo group (thyroid neo-
plasm; 1.1 per 100pt-yrs), seven in the CZP 200mg group
(three basal cell carcinomas, including one that metasta-
sized to the brain, one adrenal adenoma, one hepatic
neoplasm, one oesophageal carcinoma and one uterine
cancer; 2.3 per 100pt-yrs) and four in the CZP
400mg group (two tongue neoplasms, one extranodal
marginal-zone B-cell lymphoma and one papilloma;
1.3 per 100pt-yrs) [4]. In RAPID 2, one malignancy was
reported in each treatment group (placebo, bladder
cancer; CZP 200mg, testicular cancer; and CZP
400mg, colon cancer) [5].
The incidence of injection site pain was low for either
CZP dose group in both trials (RAPID 1: eight and seven
patients in the CZP 200mg and 400mg plus MTX groups,
respectively; RAPID 2: one patient in the CZP 400mg plus
MTX group; <3 cases per 100pt-yrs) [4, 5].
CZP monotherapy
In FAST4WARD, AEs occurred in 57.8 and 75.7% of pa-
tients in the placebo and CZP 400mg groups, respectively
(Table 4) [6]. The majority of AEs were mild to moderate;
the most common AEs in the CZP group were headache,
nasopharyngitis, upper respiratory tract infections, diar-
rhoea and sinusitis. AEs leading to withdrawal were
reported for two (1.8%) patients in the placebo
group (nausea and pneumonitis) and five (4.5%) patients
in the CZP 400mg group (bacterial arthritis, Salmonella
arthritis, increased blood creatinine/increased blood
urea, ischaemic stroke and menorrhagia). There were no
deaths.
The rate of serious infections was low, occurring in two
(1.8%) patients in the CZP 400mg group and no patients
in the placebo group, and there were no reports of tuber-
culosis. Two cases (1.8%) of benign tumours (uterine fi-
broids and benign parathyroid tumour) were reported in
the CZP 400mg group, with none in the placebo group.
No patients in the CZP 400mg group reported injection
site pain.
Conclusions
Available data from three pivotal clinical trials demonstrate
that CZP, either added to MTX or as monotherapy, im-
proves the signs and symptoms of RA as early as Week 1
FIG.3Effect of CZP on productivity in the workplace in
the RAPID 1 (Week 52) and RAPID 2 (Week 24) trials [26].
Results are shown at baseline and study end. (A) Work
days missed (absenteeism) due to arthritis per month.
(B) Days with work productivity reduced by 550%
(presenteeism) due to arthritis per month. (C)R A
interference with work productivity per month (0–10 scale,
0=no interference, 10=complete interference). The
analysis population in RAPID 1 and 2 trials was the
intention-to-treat population (employed patients only).
*P40.05 vs placebo plus MTX. Analyses were performed
using a non-parametric bootstrap t-test and the last
observation carried forward approach. Adapted from
Kavanaugh et al. [26] with permission of John Wiley &
Sons Inc.
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tural joint damage as early as 16 weeks. Patients reported
significant improvements in HRQoL and physical function,
and significant relief of arthritis pain and fatigue, following
treatment with CZP. Patients also experienced significant
improvements in productivity within and outside the
home, as well as increased participation in family, so-
cial and leisure activities with CZP. In the trials, the clinical
and functional benefits of CZP were rapid, in many
instances occurring by Week 1 of treatment, and were
sustained up to study end (1 year when administered
with MTX or 6 months when CZP was administered as
monotherapy). CZP added to MTX or as monotherapy
was well tolerated; the safety profile of CZP is similar to
that of other TNF inhibitors and CZP has a low incidence
of injection site pain.
Since CZP has only recently been approved, the effi-
cacy and safety data noted in this review are limited to
data from controlled clinical trials and do not include clin-
ical registry data. Nevertheless these data suggest that
CZP offers an important option to manage moderate to
severe RA. Clinical trials are underway to further investi-
gate the benefits of CZP in more clinically representative
patient populations, such as those who have received
DMARDs other than MTX.
Rheumatology key messages
. CZP, added to MTX or as monotherapy, improves
RA signs and symptoms and is well tolerated.
. CZP provides rapid and sustained improvements in
physical function and productivity and reductions in
pain and fatigue.
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